Highly active antiretroviral therapy: Cardiovascular risk needs to be assessed before starting treatment
AUTOR(ES)
Moerman, Filip
FONTE
BMJ Publishing Group Ltd.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=558269Documentos Relacionados
- Highly active antiretroviral therapy: Exhaustion of treatment options is a challenge that can be delayed
- Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: Effects on virologic, immunologic, and toxicity parameters
- Rapid Human Immunodeficiency Virus Decay in Highly Active Antiretroviral Therapy (HAART)-Experienced Children after Starting Mega-HAART
- Highly active antiretroviral therapy: We need to scale up its use and reach with existing facilities in poor countries
- Enteric parasitic infections in HIV/AIDS patients before and after the highly active antiretroviral therapy